With Parkinson's disease affecting millions worldwide, the need for enhanced research is both critical and immediate to improve patient outcomes and quality of life. Here, we showcase a curated selection of recent advancements in Parkinson's research.
Parkinson’s therapy risvodetinib shows good safety profile in trial: Risvodetinib, developed by Inhibikase Therapeutics for Parkinson's, showed a good safety profile in a Phase 1 trial involving both healthy volunteers and Parkinson’s patients.
4 new US sites added to global Parkinson’s genetics study: The BLAAC PD study, which is part of Global Parkinson’s Genetics Program (GP2) and aims to understand Parkinson's disease within the Black community by focusing on genetic factors, has expanded to include four new US sites, enhancing research on potential treatments.
A substantial number of Parkinson’s disease cases can be attributed to preventable risk factors, new research finds: New research from the University of Alabama at Birmingham identified preventable factors, such as head injuries and exposure to pesticides, as significant contributors to Parkinson's disease, suggesting potential for prevention.
Scientists identify how fasting may protect against inflammation: Cambridge research revealed fasting increases arachidonic acid, reducing inflammation, with implications for conditions like Parkinson's by potentially mitigating chronic inflammation linked to the disease.
Brain pathway linking movement, addiction, and rewards discovered: Researchers discovered a link between the brain's cerebellum and basal ganglia, affecting dopamine levels and movement, offering new insights for Parkinson's disease therapy by potentially targeting these pathways to alleviate symptoms.
Form of vitamin B3 may help manage Parkinson’s disease: A phase 1 clinical trial showed that high-dose vitamin B3 (NR) supplementation increases NAD+ levels in Parkinson's patients, potentially leading to symptom improvement and offering a new avenue for treatment research.
Parkinson’s disease, dementia linked to nanoplastics that may affect the brain: A Duke University study revealed nanoplastics interact with brain proteins, potentially increasing Parkinson’s and dementia risk, underscoring the need for monitoring and reducing environmental plastic pollution.
Stem-cell-derived brain cells hold promise for Alzheimer's, Parkinson's research: University of Wisconsin-Madison researchers successfully grew stem-cell-derived neurons linked to Alzheimer's and Parkinson's, offering new pathways for research and treatment development.
These achievements highlight the research community’s commitment to pushing the boundaries of understanding and treating Parkinson's disease. At Sano, we're hard at work to accelerate research in neurodegenerative conditions like Parkinson’s, offering support in patient recruitment, handling biomarker testing, and fostering long-term patient involvement.
For further details on how we can contribute to your Parkinson's disease research efforts, please get in touch below.